The death toll in the Democratic Republic of Congo’s ongoing Ebola outbreak has surpassed 3,000, according to government data released on Wednesday, prompting World Health Organization Director-General Tedros Adhanom Ghebreyesus to call for an urgent scale-up of response efforts to track elusive transmission chains in the northeast.
Ebola Outbreak Escalation and Transmission Challenges
According to World Health Organization Director-General Tedros Adhanom Ghebreyesus, tracking active transmission chains remains a primary operational challenge in the Democratic Republic of Congo. Speaking to reporters in Geneva on Wednesday, Tedros noted that many recent fatalities occurred among individuals who were not listed among known patient contacts, indicating unmonitored spread.
Furthermore, Tedros stated that unsafe burials continue to fuel transmission across the region. “Until every chain is found and broken, the epidemic will continue and will continue to pose a threat to DRC, its neighbours and the region as a whole,” he said.
The current epidemic is caused by the Bundibugyo species of Ebola. It ranks as the largest and deadliest in Congo’s history, having surpassed the 2018–2020 outbreak, and stands as the second-largest globally behind the 2014–2016 West African epidemic that infected more than 28,600 people and killed over 11,000 across Guinea, Liberia, and Sierra Leone.
Funding Shortfalls and Treatment Infrastructure Needs
The Congolese government-led Ebola response plan is currently seeking $1.3 billion in international funding to manage the epidemic. Tedros urged the international community to accelerate financial support as humanitarian assistance funding contracts globally.
The WHO has shipped 320 tons of supplies and expanded testing capacity to 3,000 tests per day. However, Luca Fontana, technical officer for health and technical logistics with the WHO, explained that maintaining a single 1,500-bed treatment center costs $15 million per month, underscoring the urgent need for additional bed capacity.
Clinical Trials for Vaccines and Antiviral Treatments
Despite ongoing challenges, health authorities report potential progress in clinical interventions. According to the WHO, two new vaccines targeting the Bundibugyo virus are currently undergoing safety trials in Britain and Canada. Because established vaccines against the Zaire Ebola virus may not be effective against the Bundibugyo strain, the WHO is working with partners to launch clinical efficacy trials in the Democratic Republic of Congo in October or November.
On the treatment front, Tedros confirmed that more than 300 Ebola patients have been enrolled in trials testing two specific therapeutics. Additionally, trials are underway evaluating the antiviral drug obeldesivir among high-risk contacts to determine whether it prevents disease after exposure to the virus.
Related reading